Pharming (PHAR) Receivables - Net (2019 - 2026)

Pharming's Receivables - Net history runs 8 years deep, the most recent figure standing at $60.0 million for Q1 2026.

• Quarterly Receivables - Net rose 26.42% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.0 million (up 26.42% YoY) and the FY2025 annual result came in at $54.7 million, changed 0.22% from the prior year.
• Receivables - Net was $60.0 million for Q1 2026 at Pharming, up from $54.7 million in the prior quarter.
• Across five years, Receivables - Net topped out at $60.0 million in Q1 2026 and bottomed at $28828.0 in Q3 2022.
• A 5-year average of $41.0 million and a median of $43.6 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net plunged 99.91% — and 2023, when it soared 140461.26%.
• Pharming's Receivables - Net stood at $27.6 million in 2022, then soared by 67.12% to $46.2 million in 2023, then climbed by 18.77% to $54.8 million in 2024, then fell by 0.22% to $54.7 million in 2025, then rose by 9.74% to $60.0 million in 2026.
• Business Quant data shows PHAR's Receivables - Net at $60.0 million in Q1 2026, $54.7 million in Q4 2025, and $43.6 million in Q3 2025.